Millennium Management LLC Reduces Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Millennium Management LLC trimmed its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 87.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 182,241 shares of the biopharmaceutical company's stock after selling 1,300,711 shares during the period. Millennium Management LLC owned approximately 0.14% of Dynavax Technologies worth $2,327,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $71,000. KBC Group NV lifted its stake in shares of Dynavax Technologies by 68.7% in the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 2,857 shares during the period. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $131,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DVAX shares. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, JMP Securities cut their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $24.00.

Dynavax Technologies Price Performance

NASDAQ DVAX traded up $0.06 on Thursday, hitting $9.95. The company had a trading volume of 1,259,805 shares, compared to its average volume of 2,200,837. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63. The company has a market capitalization of $1.19 billion, a PE ratio of 55.28 and a beta of 1.26. The company's fifty day moving average price is $10.71 and its 200-day moving average price is $12.25. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. As a group, analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.